Respiratory
diseases drugs market covers drugs that are used in the treatment of a wide
range of respiratory diseases such as asthma, chronic obstructive pulmonary
disease (COPD), chronic and acute bronchitis, emphysema and cystic fibrosis.
Some of the major drugs in the market include antimuscarinics, corticosteroids,
Codral, Coldrex and Lemsip.
Read the report at
The
substantial growth of the market from $55 billion in 2017 to nearly $71 billion
by 2021 is due to the rise in global air pollution levels which will lead to
higher number of respiratory diseases.
In the
report, the global respiratory drugs market is divided into two segments,
namely, anti-asthmatics and COPD drugs and cough and cold preparations. While
the first segment accounts for more than three-fifth of the market and the
remaining share is accounted for the other segment.
Download a sample of the report at
The USA was the largest country in the respiratory diseases drugs
market in 2017, accounting for nearly two-fifth of the market share. This can
be attributed to the large number of patients suffering from asthma and chronic
obstructive pulmonary diseases (COPD).
The
respiratory drugs market is fragmented with a number of small drug organizations.
The top five competitors in the market made up nearly 50% of the total market
in 2017. GlaxosmithKline Plc. was the largest competitor of the market,
followed by AstraZeneca Plc., Merck & Co, Novartis AG and Johnson &
Johnson. GlaxosmithKline Plc. was founded in 1715 and is headquartered in
Brentford, UK. It is involved in creating, discovering, developing,
manufacturing, and marketing of vaccines, over-the-counter medicines, and
health-related consumer products globally.
About
The Business Research Company.
The
Business Research Company is a Business Intelligence Company which excels in
company, market and consumer research. It has
offices in the UK, the US and India and a network of trained researchers in 15
countries globally.
Contact
Information.
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
No comments:
Post a Comment